ORGANOGENESIS HOLDINGS INC CLASS A (ORGO)
Health Care · Advanced wound care and tissue engineering · NASDAQ
Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance.
What ORGANOGENESIS HOLDINGS INC CLASS A does
Organogenesis develops and commercializes wound care and surgical products, including advanced skin substitutes and dermal matrices used in treating acute and chronic wounds, burns, and surgical reconstruction. The company manufactures and distributes both proprietary biologic and synthetic tissue-engineered products through a direct sales force and distribution network, generating revenue from net product sales and government grants. The company faces significant revenue fluctuation and operates in a highly regulated healthcare environment subject to Medicare reimbursement policies and FDA oversight.
Themes: ["Wound care / tissue repair","Regenerative medicine","Surgical reconstruction","DME reimbursement and coverage"]
Fundamentals
- Price$2.46 as of 2026-07-09 close
- Market cap$317M as of 2026-07-10
- 1-year return-44.8% as of 2026-07-09 close
- P/E116.65 as of 2026-07-10
- Net margin+0.5% as of 2026-07-10
- Gross margin+72.9% as of 2026-07-10
- ROE+0.7% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)+12.2% as of 2026-07-10
- Revenue CAGR (3y)+7.8% SEC XBRL
- Beta1.35 as of 2026-07-10
Key risks (from latest filing)
["Significant dependency on Medicare reimbursement rates and coverage policies for durable medical equipment; changes in Medicare payment policy or shifts toward competitor products could materially impact revenue","Rapid technological change and competition from alternative wound treatment modalities (negative-pressure wound therapy, hyperbaric oxygen) may render existing products obsolete if R&D efforts fail to produce timely product enhancements with adequate reimbursement","Regulatory and compliance risks including potential FDA product recalls, government investigations for non-compliance, and possible sanctions that could halt sales or require costly remediation"]
Competitors & peers
- Smith & Nephew (SN)
- Zimmer Biomet (ZBH)
- Medtronic (MDT)
- Integra LifeSciences (IART)
- Coloplast (COLOF)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.